Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04150744
PHASE2

RFA Plus Carrizumab vs Carrizumab Alone for HCC

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

View on ClinicalTrials.gov

Summary

The study aims to find whether patients with advanced HCC can get more benefits from RFA +PD-1 immunosuppressant (carrizumab) compared with carrizumab alone, considering with the result of PFS.

Official title: Radiofrequency Ablation Plus Carrizumab vs Carrizumab Alone for Moderate or Advanced Hepatocellular Carcinoma: A Real World Study

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2020-08-01

Completion Date

2026-12-30

Last Updated

2020-07-08

Healthy Volunteers

Yes

Interventions

COMBINATION_PRODUCT

radiofrequency ablation

take advantage of RFA to destroy hepatocellular carcinoma by high temperature

Locations (1)

the Second Affiliated Hospital of Zhejiang University

Hangzhou, Zhejiang, China